MarginsXMarginsX
Home › Markets › Health Care › CURX

Curanex Pharmaceuticals Inc (CURX)

CURX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$4.63
-0.11% on the day
Market cap
$7.3M
Nano cap
Revenue
Recent IPO: no annual report filed yet
Net income
Recent IPO: no annual report filed yet

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerCURX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2025
SEC CIK0002025942
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials

Recent IPO: no annual report filed yet.

Warning signs

Cash runway
2.9 months
$2.9M cash at June 30, 2026
Share count, 1 year
+10.7%
2025-11-14 to 2026-11-13
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"These conditions raise substantial doubt about the Company's ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$2.9M cash; operating cash flow -$3.0M a quarter.Report 2026-06-30
Shares outstanding1,568,216 (2026-11-13); 28,340,812 a year earlier. 1y figure adjusted for split (1-for-20 overall).Cover page 2026-11-13
Reverse splits, 3 years1; latest 1-for-20 on 2026-08-20Source 2026-08-20
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKreit & Chiu CPA LLP, Los Angeles, California, United StatesPCAOB Form AP 2026-04-22
Late filings, 12 months1 NT noticeNT 10-Q 2025-11-17
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
Not filed-$3.3M-$1.1M$2.9MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2026
2026-03-31
Not filed-$3.2M-$955K$4.0MNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2025
2025-12-31
Not filed-$3.1M-$857K$5.0MNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2025
2025-09-30
Not filed-$954K-$9.2M$5.8MNo debt tagsNeeds four quarters10-Q 2025-11-17
Q2 2025
2025-06-30
Not filed-$60K-$290K$109KNo debt tagsNeeds four quarters10-Q 2026-08-14
Q1 2025
2025-03-31
Not filed-$138K-$150KNot filedNo debt tagsNeeds four quarters10-Q 2026-08-14
Q4 2024
2024-12-31
Not filed-$146K-$95K$149KNo debt tagsNeeds four quarters10-K 2026-03-30
Q3 2024
2024-09-30
Not filed-$91K-$130KNot filedNo debt tagsNeeds four quarters10-Q 2025-11-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B42025-08-26
Latest annual report10-K2026-03-30
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-10-19

Source: SEC EDGAR submissions feed, 66 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-22.7%
1 month-1.6%
3 months+9.6%
Year to date-27.5%
1 year-56.6%
From 52-week high-54.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
IMRNImmuron Limited$0.8996+2.23%$7.3M
GTBPGT Biopharma Inc.$3.54-1.81%$7.3M
LGVNLongeveron Inc.$2.14-14.06%$7.2M
UPCUniverse Pharmaceuticals Inc.$1.48-1.99%$7.4M
XCURExicure Inc.$1.07-0.93%$7.0M
MBRXMoleculin Biotech Inc.$7.14-9.28%$7.6M
TPSTTempest Therapeutics Inc.$0.3418-10.50%$6.8M
SNGXSoligenix Inc.$0.2882-10.22%$6.7M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier